Advertisement

Topics

Cyclacel Limited Company Profile

11:01 EST 21st November 2017 | BioPortfolio

Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200; CYC400), Penetratin®-small molecule complexes (CYC300), Pimetic™ small molecules mimicking natural cancer suppressing genes (CYC100), and intelligent delivery and targeting systems (Penetratin® and SGC™ technologies). Cyclacel’s Polgen division (Cambridge, UK) is in a world-first effort to validate, develop assays and discover drugs arising from 100 genomic targets regulating cancer mitosis. CYC202, the lead drug candidate is entering Phase I this autumn as the 3rd entry in a worldwide race involving several pharmaceutical majors.

Cyclacel’s clinical strategy for CYC202 includes several Phase I and Phase II trials in patients with solid tumors with the objective of defining the most attractive population to test the drug’s properties, as well as studying pharmacokinetics and optimal dosing. The commercialization strategy calls for positioning the company’s CDK inhibitors as modern, mechanism-based medicines with low toxicity and high target specificity to be used for treating cancer as a chronic disease. CDK inhibitors in general, and CYC202 in particular, have shown activity in animal models of non-cancerous hyperproliferative diseases such as autoimmune, cardiovascular, dermatological and inflammatory conditions.

Location

James Lindsay Place; Dundee Technopole
Dundee
Tayside
DD1 5JJ
United Kingdom

Contact

Phone: 44 1382 206 062
Fax: 44 1382 206 067
Email: srombotis@cyclacel.com


News Articles [41 Associated News Articles listed on BioPortfolio]

Public offering nets $14.1mm for Cyclacel

Cyclacel Pharmaceuticals Inc. (cell cycle biology-based drug discovery for cancer, metabolic, renal, and respiratory diseases) netted $14.1mm through a public offering. The company issued 3.15mm Class...

Cyclacel raises $13.2M in follow-on

Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using c...

Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral th...

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using ...

Cyclacel Pharma Reports Second Quarter 2017 Financial Results

  Life Sciences Jobs   ...

Cyclacel Pharmaceuticals (CYCC) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigate...

Clinical Trials [0 Results]

None

Companies [83 Associated Companies listed on BioPortfolio]

Cyclacel Limited

Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200; ...

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious ...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

More Information about "Cyclacel Limited" on BioPortfolio

We have published hundreds of Cyclacel Limited news stories on BioPortfolio along with dozens of Cyclacel Limited Clinical Trials and PubMed Articles about Cyclacel Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cyclacel Limited Companies in our database. You can also find out about relevant Cyclacel Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record